PNS vs RFA for Facet Joint Pain

Sponsor
Penn State University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05952518
Collaborator
(none)
70
2
48

Study Details

Study Description

Brief Summary

Radiofrequency ablation of the medial nerve is the current surgical treatment for back pain originating from the facet joints in the spine. However, this procedure causes denervation of spinal muscles. Peripheral nerve stimulation is another treatment for facet joint pain that may not cause damage to the spinal muscles. This study will compare both treatments in terms pain relief and spine biomechanics.

Condition or Disease Intervention/Treatment Phase
  • Device: Sprint PNS system
  • Procedure: Radiofrequency Ablation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of Peripheral Nerve Stimulation as an Alternative to Radiofrequency Ablation for Facet Joint Pain
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2026
Anticipated Study Completion Date :
Oct 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Peripheral Nerve Stimulation

Peripheral nerve stimulation (PNS) is a procedure used to relieve chronic back pain by targeting the nerves responsible for transmitting pain signals from the back to the brain. It is a minimally invasive approach that aims to disrupt the pain signals and provide pain relief.

Device: Sprint PNS system
Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator

Active Comparator: Radiofrequency Ablation

Radiofrequency ablation (RFA) is the current standard of care for facet joint pain. It is a minimally invasive procedure used to relieve chronic back or neck pain caused by issues with the small joints in the spine called facet joints.

Procedure: Radiofrequency Ablation
Thermal ablation of the medial nerve

Outcome Measures

Primary Outcome Measures

  1. Multifidus muscle activity [pre-treatment]

    Muscle contraction quantification via shear wave elastography

  2. Multifidus muscle activity [within two weeks of treatment completion]

    Muscle contraction quantification via shear wave elastography

  3. Multifidus muscle activity [12 months after pre-treatment measurement]

    Muscle contraction quantification via shear wave elastography

Secondary Outcome Measures

  1. Pain Intensity [pre-treatment]

    Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.

  2. Pain Intensity [within two weeks of treatment completion]

    Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.

  3. Pain Intensity [12 months after pre-treatment measurement]

    Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.

  4. Oswestry Disability Index [pre-treatment]

    Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled

  5. Oswestry Disability Index [within two weeks of treatment completion]

    Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled

  6. Oswestry Disability Index [12 months after pre-treatment measurement]

    Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled

  7. PROMIS-29 v2.0 [pre-treatment]

    Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)

  8. PROMIS-29 v2.0 [within two weeks of treatment completion]

    Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)

  9. PROMIS-29 v2.0 [12 months after pre-treatment measurement]

    Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)

  10. isometric back strength [pre-treatment]

    Measurement of peak force generated by the torso in extension in Newtons

  11. Isometric back strength [within two weeks of treatment completion]

    Measurement of peak force generated by the torso in extension in Newtons

  12. isometric back strength [12 months after pre-treatment measurement]

    Measurement of peak force generated by the torso in extension in Newtons

  13. Functional Reach [pre-treatment]

    distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.

  14. Functional Reach [within two weeks of treatment completion]

    distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.

  15. Functional Reach [12 months after pre-treatment measurement]

    distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.

  16. Repetitive Trunk Rotation [pre-treatment]

    Time to complete 20 rotations, seconds, longer times are worse performance.

  17. Repetitive Trunk Rotation [within two weeks of treatment completion]

    Time to complete 20 rotations, seconds, longer times are worse performance.

  18. Repetitive Trunk Rotation [12 months after pre-treatment measurement]

    Time to complete 20 rotations, seconds, longer times are worse performance.

  19. Repeated Chair Stands [pre-treatment]

    Time to perform 5 repeated chair stands, higher times mean worse outcomes.

  20. Repeated Chair Stands [within two weeks of treatment completion]

    Time to perform 5 repeated chair stands, higher times mean worse outcomes.

  21. Repeated Chair Stands [12 months after pre-treatment measurement]

    Time to perform 5 repeated chair stands, higher times mean worse outcomes.

  22. Pfirmmann grade [pre-treatment]

    Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.

  23. Pfirmmann grade [within two weeks of treatment completion]

    Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.

  24. Pfirmmann grade [12 months after pre-treatment measurement]

    Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.

  25. t2-relaxation time [pre-treatment]

    T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.

  26. t2-relaxation time [within two weeks of treatment completion]

    T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.

  27. t2-relaxation time [12 months after pre-treatment measurement]

    T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.

  28. 2-point dixon MRI [pre-treatment]

    Intramuscular fat percentage, higher percentage means worse outcome.

  29. 2-point dixon MRI [within two weeks of treatment completion]

    Intramuscular fat percentage, higher percentage means worse outcome.

  30. 2-point dixon MRI [12 months after pre-treatment measurement]

    Intramuscular fat percentage, higher percentage means worse outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age range (18-80 years): The age range of the patient population at Hershey Medical Center with facet pain is 24 to 90 years old, with a mean age of 63 years old. Due to the physical tests planned in the study, the maximum age limit will be restricted to 80 years old.

  2. English Speaking: Adults who only speak other languages will not be included because of the lack of feasibility of employing reliable instruments and interviewers fluent in other languages.

  3. Facet Joint Pain: male and female patients having a diagnosis of facet joint pain based upon accepted diagnostic criteria (i.e., two positive nerve blocks) and assessed by an experienced physical therapist or physician.

  4. Indication for Surgical Procedure: Physical therapy is the first line of action for facet joint pain. If PT is not effective, patients are eligible for RFA or PNS.

Exclusion Criteria:
  1. Previous Spinal Conditions Surgery: We will exclude patients with other spinal conditions like scoliosis or who have received previous spinal surgeries.

  2. Systemic neurological or neuromuscular disease: Such disorders (e.g., stroke, muscular dystrophy, myopathies) affect muscle and may confound muscle data and/or balance and physical performance data.

  3. Allergic reaction to ultrasound gels: It is possible, although rare, that patients develop allergic reaction to ultrasound gels. Those subjects will be excluded from the study.

  4. Physical Activity: Subjects will be asked to fill out the Physical Activity Readiness Questionnaire (PAR-Q), and if they answer yes to any of the questions, they need to be cleared by their physician prior to participating in the study.

  5. Current infection, illness, or condition: Individuals with a current infection, illness, or condition (e.g., uncontrolled blood pressure, pregnancy) that may affect their ability to safely participate will be excluded.

  6. Mental incompetency: Individuals who cannot legally consent themselves to the surgical procedure and participation in the research study, will not be considered for inclusion.

  7. Patients who have a Deep Brain Stimulation (DBS) system.

  8. Patients who have an implanted active cardiac implant (e.g. pacemaker or defibrillator).

  9. Patients who have any other implantable neuro-stimulator whose stimulus current pathway may overlap with that of the SPRINT System.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Penn State University

Investigators

  • Principal Investigator: Daniel H. Cortes, Ph.D., Penn State University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Daniel Cortes, Associate Professor, Penn State University
ClinicalTrials.gov Identifier:
NCT05952518
Other Study ID Numbers:
  • STUDY00022997
First Posted:
Jul 19, 2023
Last Update Posted:
Jul 19, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 19, 2023